Maxim Group analyst Anthony Vendetti reiterated a Hold rating on Aethlon Medical (AEMD – Research Report) yesterday. The company’s shares closed yesterday at $1.64.
Vendetti covers the Healthcare sector, focusing on stocks such as Sensus Healthcare, cbdMD, and Guardion Health Sciences. According to TipRanks, Vendetti has an average return of -1.3% and a 32.80% success rate on recommended stocks.
Aethlon Medical has an analyst consensus of Hold.
See the top stocks recommended by analysts >>
The company has a one-year high of $7.20 and a one-year low of $1.40. Currently, Aethlon Medical has an average volume of 17.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aethlon Medical (AEMD) Company Description:
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
Read More on AEMD:
